- Global Pharma News & Resources

Forge Biologics to Participate in Upcoming Investor Conferences and Presentations in March 2022

COLUMBUS, Ohio--(BUSINESS WIRE)--#genetherapy--Forge Biologics, a gene therapy-focused contract development and manufacturing organization, announced today that members of the Company’s leadership team will be participating at the following upcoming investor conferences in March:

Cowen 42nd Annual Virtual Health Care Conference


March 7-9, 2022


1x1 investor meetings



Oppenheimer Fireside Chat


March 14, 2022


11:00 a.m. Eastern Time


“AAV-based Gene Therapy: Navigating Regulatory and CMC Landscape”


Timothy J. Miller, Ph.D., Chief Executive Officer of Forge Biologics


RA Session, II, Chief Executive Officer of Taysha Gene Therapies


Rachel Potter, Ph.D., Head of Gene Therapy Research at Sarepta Therapeutics


Kevin DeGeeter, Senior Analyst, Biotechnology and Diagnostics


Hartaj Singh, Senior Analyst, Biotechnology



Oppenheimer 32nd Annual Virtual Healthcare Conference


March 15-17, 2022


1x1 investor meetings




March 17, 2022


10:40 a.m. Eastern Time


Company presentation


Timothy J. Miller, Ph.D., CEO, President and Co-Founder of Forge Biologics

Dr. Miller’s Oppenheimer company presentation will be delivered via live webcast and may be accessed for 90 days by visiting Forge’s Events website at

About Forge Biologics

Forge Biologics is a hybrid gene therapy contract manufacturing and clinical-stage therapeutics development company. Forge’s mission is to enable access to life changing gene therapies and help bring them from idea to reality. Forge has a 200,000 square foot facility in Columbus, Ohio, The Hearth, to serve as its headquarters. The Hearth is a custom-designed cGMP facility dedicated to AAV vector manufacturing and will host end-to-end manufacturing services to accelerate gene therapy programs from preclinical through clinical and commercial stage manufacturing. By taking a patients-first approach, Forge aims to accelerate the timelines of these transformative medicines for those who need them the most. To learn more, visit


Media Inquiries
Marina Corleto
Senior Manager, Marketing and Communications

Business Development
Magdalena Tyrpien
Senior Vice President, Head of Business Development

Client Development
John Maslowski
Chief Commercial Officer

Investor Relations
Christina Perry
Senior Vice President, Finance and Investor Relations

Editor Details

  • Company:
    • Businesswire
Last Updated: 07-Mar-2022